SMSigne Bruun Munksgaard

Signe Bruun Munksgaard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Signe Bruun Munksgaard has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial

    by Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen, Lars Bendtsen

    Medication-overuse headache leads to high disability and decreased quality of life, and the best approach for withdrawal has been debated. To compare change in disability and quality of life between two withdrawal programs. We randomized medication-overuse headache patients to program A (two months without acute analgesics or migraine medications) or program B (two months with acute medications restricted to two days/week) in a prospective, outpatient study. At 6 and 12 months, we measured disability and headache burden by the Headache Under-Response to Treatment index (HURT). We estimated quality of life by EUROHIS-QOL 8-item at 2-, 6-, and 12-month follow-up. Primary endpoint was disability change at 12 months. We included 72 medication-overuse headache patients with primary migraine and/or tension-type headache. Fifty nine completed withdrawal and 54 completed 12-month follow-up. At 12-month follow-up, 41 patients completed HURT and 38 completed EUROHIS-QOL 8-item. Disability reduction was 25% in program-A and 7% in program-B (p = 0.027). Headache-burden reduction was 33% in program-A and 3% in program-B (p = 0.005). Quality of life was increased by 8% in both programs without significant difference between the programs (p = 0.30). At 2-month follow-up, quality of life increased significantly more in program-A than program-B (p = 0.006). Both withdrawal programs reduced disability and increased quality of life. Withdrawal without acute medication was the most effective in reducing disability in medication-overuse headache patients. Clinicaltrials.gov (NCT02903329).


  • Treatment of medication overuse headache—A review

    by Signe Bruun Munksgaard, Samuel Kjær Madsen, Troels Wienecke

    Medication overuse headache (MOH) is the most prevalent chronic headache disorder with a prevalence between 1‐2% worldwide. The disease has been acknowledged for almost 30 years, yet experts still disagree on how best to treat MOH. By performing a search in PubMed on the terms “medication overuse headache”, “analgesics abuse headache”, “rebound headache”, “drug induced headache”, and “headache AND drug misuse” limited to human studies published in English between January 1st 2004 and November 1st 2017, we aimed to evaluate current literature concerning predictors of treatment outcome, inpatient and outpatient treatment programs, initial versus latent administration of prophylactic medications, and to review the effect of prophylactic medications. Selection criteria were prospective, comparative or controlled trials on treatment of MOH in persons of at least 18 years of age. Several studies evaluated risk factors to predict the outcome of MOH treatment, but many studies were underpowered. Psychiatric comorbidity, high dependence score and overuse of barbiturates, benzodiazepines and opioids predicted a poorer outcome of withdrawal therapy. Patients with these risk factors benefit from inpatient treatment, whereas patients without risk factors benefit equally from in and outpatient treatment. Some medications for migraine prophylactics have shown better effect on MOH compared with placebo, but not when combined with withdrawal. We conclude that detoxification programs are of great importance in MOH treatment. Latent administration of prophylactic medications reduces the number of patients needing prophylactic medication. Individualizing treatment according to the predictors of outcome may improve treatment outcome and thus reduce work‐related and treatment‐related costs.


  • Circulating nociceptin and CGRP in medication‐overuse headache

    by Signe Bruun Munksgaard, Csaba Ertsey, Erik Frandsen, Lars Bendtsen, Kornelia Tekes, Rigmor Højland Jensen

    Background Previous studies found low serum levels of nociceptin in migraine patients but high serum levels of calcitonin gene‐related peptide (CGRP). CGRP can elicit migraine‐like headache. Medication‐Overuse Headache (MOH) often has migraine features and can mimic chronic migraine. We therefore hypothesized that as in migraine, serum levels of nociceptin would be lower and CGRP serum levels higher in MOH patients compared with those in healthy volunteers. We hypothesized the serum levels would normalize after detoxification. Methods Seventeen MOH patients, hereof 70.6% with chronic migraine and MOH, and 30 sex and age matched headache‐free controls were included. MOH patients underwent a 2‐month out‐patient detoxification program and after six months 10 patients and 19 controls were retested. Blood samples were analyzed blinded. Results We found no differences in the levels of nociceptin and CGRP between MOH patients and controls (p=0.65 and p=0.59). The mean headache frequency reduction was 43% and 70% of patients reverted to episodic headache after 6 months, but the levels of nociceptin and CGRP were unchanged (p=0.71 and p=0.82). Conclusion In contrast to previous findings in migraine patients, we found normal serum levels of nociceptin and CGRP in MOH patients. Thus, we find no evidence that the increased headache frequency of MOH patients could be caused by altered nociceptin and CGRP levels. This underlines the importance of identifying medication overuse in chronic headache and treating the MOH.


  • Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project

    by Pernille Linde Jellestad, Louise Ninett Carlsen, Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Miguel Lainez, Ricardo Fadic, Zaza Katsarava, Maria Teresa Goicochea, Santiago Spadafora, et al.

    Medication-overuse headache is a costly disease for individuals and society. To estimate the impact of medication-overuse headache treatment on direct and indirect headache-related health care costs. This prospective longitudinal study was part of the COMOESTAS project (COntinuous MOnitoring of Medication Overuse Headache in Europe and Latin America: development and STAndardization of an Alert and decision support System). Patients with medication-overuse headache were included from four European and two Latin American headache centers. Costs of acute medication, costs of health care services, and measurements of productivity were calculated at baseline and at 6-month follow-up Treatment consisted of overused drug withdrawal with optional preventive medication. A total of 475 patients (71%) completed treatment and were followed up for 6 months. Direct health care costs were on average reduced significantly by 52% (p < 0.001) for the total study population. Significant reductions were seen in both number of consumed tablets (−71%, p < 0.001) and number of visits to physicians (−43%, p < 0.001). Fifty percent of patients reduced their number of consumed tablets ≥ 80%. Headache-related productivity loss, calculated either as absence from work or ≥ 50% reduction of productivity during the workday, were reduced by 21% and 34%, respectively (p < 0.001). Standardized treatment of medication-overuse headache in six countries significantly reduced direct health care costs and increased productivity. This emphasizes the importance of increasing awareness of the value of treating medication-overuse headache. The trial was registered at ClinicalTrials.gov (no. NCT02435056)


  • Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial

    by Louise Ninett Carlsen, Signe Bruun Munksgaard, Rigmor Højland Jensen, Lars Bendtsen

    There is lack of evidence on how to detoxify medication-overuse headache. To compare the effect of complete stop of acute medication with restricted intake. Medication-overuse headache patients were included in a prospective, outpatient study and randomized to two months’ detoxification with either a) no analgesics or acute migraine-medication (program A), or b) acute medication restricted to two days/week (program B). Detoxification was followed by preventives if indicated. Patients were followed up at 2, 6 and 12 months. Percentage reduction in headache days/month after 6 months was the primary outcome. We included 72 medication-overuse headache patients with a primary migraine and/or tension-type headache diagnosis. Fifty-nine completed detoxification, 58 (81%) were followed up at month 6 and 53 (74%) at month 12. At month 6, program A reduced headache days/month by 46% (95% CI 34–58) compared with 22% (95% CI 11–34) in program-B (p = 0.005), and 70% in program A versus 42% in program B were reverted to episodic headache (p = 0.04). Migraine-days/month were reduced by 7.2 in program A (p < 0.001) and 3.6 in program B (p = 0.002) after 6 months. Both detoxification programs were very effective. Detoxification without analgesics or acute migraine-medication was the most effective program. Clinicaltrials.gov (NCT02903329).


    • 26 September 2016
      • Vol. 178  (39)

    [Clinical presentation and treatment of medication-overuse headache].

    by Louise Ninett Carlsen, Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Rigmor Højland Jensen

    Medication-overuse headache (MOH) is a disabling, costly and often overlooked disorder. The prevalence in Denmark is 1.8% equivalent to 80.000-100.000 adults. The aim is to increase awareness of clinical presentation and treatment options for patients with MOH when encountered in primary care setting, exemplified by three representative cases. Clinical presentation of MOH and three treatment approaches are discussed. MOH is a chronic disorder which is preventable and treatable.

  • Open Access

    Medication-overuse headache: a perspective review

    by Maria Lurenda Westergaard, Signe Bruun Munksgaard, Lars Bendtsen, Rigmor Højland Jensen

    Medication-overuse headache (MOH) is a debilitating condition in which frequent and prolonged use of medication for the acute treatment of pain results in the worsening of the headache. The purpose of this paper is to review the most recent literature on MOH and discuss future avenues for research. MOH accounts for a substantial share of the global burden of disease. Prevalence is often reported as 1–2% but can be as high as 7% overall, with higher proportions among women and in those with a low socioeconomic position. Management consists of withdrawing pain medication, focusing on prophylactic and nonmedical treatments, and limiting acute symptomatic medication. Stress reduction and lifestyle interventions may support the change towards rational pain medication use. Support, follow up, and education are needed to help patients through the detoxification period. There is fertile ground for research in MOH epidemiology, pathophysiology, and neuroimaging. Randomized and long-term follow-up studies on MOH treatment protocols are needed. Further focused research could be of major importance for global health.


  • Open Access

    Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study

    by COMOESTAS Consortium, Ninett Louise Find, Rossana Terlizzi, Signe Bruun Munksgaard, Lars Bendtsen, Cristina Tassorelli, Giuseppe Nappi, Zaza Katsarava, Miguel Lainez, Maria Teresa Goicochea, et al.

    Medication overuse headache (MOH) is a very disabling and costly disorder due to indirect costs, medication and healthcare utilization. The aim of the study was to describe general demographic and clinical characteristics of MOH, along with the national referral pathways and national painkillers distribution in several European and Latin American (LA) Countries. This descriptive cross-sectional observational study included 669 patients with MOH referred to headache-centers in Europe and LA as a part of the COMOESTAS project. Information about acute medication and healthcare utilization were collected by extensive questionnaires, supplemented with structured patient interviews. Triptans were overused by 31 % European patients and by 6 % in LA (p < 0.001), whereas ergotamines were overused by 4 % in Europe and 72 % in LA (p < 0.001). Simple analgesics were overused by 54 % in Europe and by 33 % in LA (p < 0.001), while combination-analgesics were more equally overused (24 % in Europe and 29 % in LA). More European patients (57 %) compared with LA patients (27 %) visited general practitioners (p < 0.001), and 83 % of European patients compared to 38 % in LA consulted headache specialists (p < 0.001). A total of 20 % in Europe and 30 % in LA visited emergency rooms (p = 0.007). There are marked variations between LA and Europe in healthcare pathways and in acute medication overuse regarding patients with MOH. This should be considered when planning prevention campaigns against MOH.


  • Open Access

    Superior Orbital Fissure Syndrome and Ophthalmoplegia Caused by Varicella Zoster Virus with No Skin Eruption in a Patient Treated with Tumor Necrosis Alpha Inhibitor

    by Helene Jensen, Sidsel Thorup Thomsen, Stine Scott Hansen, Signe Bruun Munksgaard, Mette Lindelof

    Varicella zoster virus lies dormant in the dorsal root ganglia after symptomatic chicken pox infection, usually in childhood. If the virus reactivates in the trigeminal ganglia, it can cause varicella zoster ophthalmicus, which can have severe ocular complications. We report a case of a 73-year-old woman in severe immunosuppression due to treatment with mycophenolate mofetil, glucocorticosteroids and a tumor necrosis factor alpha inhibitor. The reactivation caused superior orbital fissure syndrome, which has only rarely been described in relation to varicella zoster virus reactivation. In our case, the syndrome was seen along with severe encephalitis.